

# Considerations for Implementation of Cabenuva Use in Clinical Practice

Cabenuva is co-packaged into a kit containing cabotegravir extended-release (CAB LA) injectable suspension with rilpivirine extended-release (RPV LA) injectable suspension<sup>1</sup>



CAB LA 600 mg/3 mL  
RPV LA 900 mg/3 mL




CAB LA 400 mg/2 mL  
RPV LA 600 mg/2 mL

Figure 1. Dosing Kits

Cabenuva, a 2-drug co-packaged product of cabotegravir, an HIV-1 INSTI, and rilpivirine, an HIV-1 NNRTI, is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Monthly Dosing Schedule of Cabenuva <sup>1</sup>				Every 2 Month Dosing Schedule of Cabenuva <sup>1</sup>			
Month 1 OLI* (minimum 28 days)		Month 2 Initiation phase	Month ≥ 3 Continuation phase	Month 1 OLI* (minimum 28 days)		Month 2 and 3 Initiation phase	Month ≥ 5 Continuation phase
Previous ART	<b>CAB tablet</b> Daily oral dose (30 mg)	<b>CAB LA</b> Single IM injection (600 mg, 3 mL)	<b>CAB LA</b> Q1M IM injections (400 mg, 2 mL)	Previous ART	<b>CAB tablet</b> Daily oral dose (30 mg)	<b>CAB LA</b> Single IM injection (600 mg, 3 mL)	<b>CAB LA</b> Q2M IM injections (600 mg, 3 mL)
	<b>RPV tablet</b> Daily oral dose (25 mg) taken with a meal	<b>RPV LA</b> Single IM injection (900 mg, 3mL)	<b>RPV LA</b> Q1M IM injections (600 mg, 2mL)		<b>RPV tablet</b> Daily oral dose (25 mg) taken with a meal	<b>RPV LA</b> Single IM injection (900 mg, 3mL)	<b>RPV LA</b> Q2M IM injections (900 mg, 3mL)
*OLI (oral lead-in) is optional and may be used to assess tolerability		Initiate injections on the final day of the OLI (if used) or the patient may go directly to injections	Both IM injections given once a month, at separate gluteal injections sites during same visit	*OLI (oral lead-in) is optional and may be used to assess tolerability		Initiate injections on the final day of the OLI (if used) or the patient may go directly to injections	Second injection is given one month after the first
				All subsequent injections are given every two months			

## Overview of the Implementation Journey of Cabenuva in Clinical Practice<sup>1-2</sup>



## Considerations for Clinic Preparation<sup>3</sup>

CUSTOMIZE was an implementation-effectiveness study to inform clinical practice around implementation of Cabenuva. Some of this information may be useful for varying clinic types.

Additional information on CUSTOMIZE:

For Office Staff Perspectives, please click



For Patient Perspectives, please click



Injection education programs are available through ViiV Healthcare by contacting a regional sales representative...



For higher BMI individuals (e.g. > 30 kg/m<sup>2</sup>), consider a **2-inch needle** (not included in kit). For more details, please click the hand icon.



Important safety information is found in the attached Prescribing Information.

For more information



MI Letter



Prescribing Information



CLICK FOR **ViiV US Medical Portal**

Some information contained in this response may not be included in the approved Prescribing information. This response is not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. Please note that reports of adverse events in the published literature often lack causality assessments and may contain incomplete information; therefore, conclusions about causality generally cannot be drawn. In order for ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877-844-8872. Please consult the attached Prescribing Information. This response was developed according to the principles of evidence-based medicine and, therefore, references may not be all-inclusive.

**Abbreviations:** ART = antiretroviral therapy; CAB = cabotegravir tablets; CAB LA = long-acting cabotegravir; cu ft = cubic-foot; HCP = health care professional; HIV-1 = human immunodeficiency virus type 1; IM = intramuscular; INSTI = integrase strand transfer inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; RPV = rilpivirine tablets; RPV LA = long-acting rilpivirine; RNA = ribonucleic acid; OLI = oral lead-in; Q1M = once-monthly; Q2M = every 2 month.

**References:** 1. ViiV Healthcare Local Label; 2. Data on File. 2019N425811; 3. Data on File. CUSTOMIZE (Study 209493). Available at <http://www.viiv-studyregister.com>